Appreciatingthis, Kim et al. developed theranostic agent 39 (Figure 16) composed of anNSAID (indomethacin) linked to SN-38 through a nitrobenzyl alcohol-basedlinker.206 The incorporation of indomethacinin the theranostic design satisfied two roles; to achieve tumor targetingbased on COX-2 overexpression, as well as angiogenesis inhibitionmediated by COX-2. The gene discussed is PTGS2; the disease is neoplasm.